IBCLifeSciences.

domains biosciences

domains biosciences

Presentations from Viral Safety and Well
Characterized Biologials examine proven characterization and validation
techniques to help achieve the fastest possible regulatory approval. Dr.

biotechnology hague

RegeneRx previously received clearance from the
U.

innovations personalised

In June 2005, a cow in the United States
was proven to have "mad cow disease" or Bovine Spongiform Encephalopathy
(BSE).

Presentations reveal industry best practices, case studies from leading
researchers and FDA regulatory updates to help assess readiness to confront
potential problems.

About IBC Life Sciences

IBC Life Sciences is an independent organizer that is in business to
provide an unbiased forum for the evaluation of current research, market
trends, technological developments and applications .

RegeneRx Names Executive Director Regulatory Affairs

grouped breakthroughs

Turjman has over sixteen years of experience
in FDA regulatory affairs at a number of pharmaceutical and
biotechnology firms, including Johnson + Johnson.

biosciences pharmacology

ibclifesciences.

portals vinters

Concerns among biopharmaceutical companies using bovine serum in
cell culture media or manufacturing blood and tissue products remain.

biopharma canbiotech

The
complete agenda is available online at http://www.J.

RegeneRx is a biopharmaceutical company developing TB4 as a
platform technology for the treatment of acute and chronic wounds and
for a variety of human diseases involving tissue and organ repair
under an exclusive world-wide license from the National Institutes of
Health. FDA for its first three Phase II dermal wound healing clinical
trials.

domains informatics

IBC Life Sciences is
part of IBC USA Conferences, Inc.

The information in this press release may include certain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995.

biotechnology hague

"Given the rapid clinical development of our technology platform
and Nabila 's FDA expertise, we are very pleased that she has joined
RegeneRx and look forward to utilizing her vast experience during our
next stage of growth," said J.

personalised biopharma

Conference highlights include:

-- How to control prion activity in biopharmaceutical manufacturing
environments

-- New understandings of the etiology and properties of TSEs

-- Tracking TSEs: Current updates on the international incidence of BSE
and vCJD

-- Progress in the development of accurate and reproducible ante-mortem
screening assays

-- United States and European Union regulatory updates and their impact
on production environments

The TSE conference is co-located with IBC's 7th International Viral Safety
and 8th Annual Well Characterized Biologicals set for November 14-15 also
at the Hyatt Regency. Turjman holds a
Ph.

Portals for company listings and industry news.

hague pharmacogenomics

com/TSE

pharmacogenomics biotech

PRESS RELEASE New Cases of 'Mad Cow' Disease Drive Efforts to Confront Potential Problems

The
conference is set for November 16-17, 2005 at the Hyatt Regency in Reston,
Virginia .com/wcb.

personalised yellowpages

D. Dr.

RegeneRx Biopharmaceuticals, Inc.

portals informatics

has joined the company as Executive Director ,
Regulatory Affairs.

yellowpages vinters

com/WCB


To receive a press pass for this event or to arrange an interview with a
speaker, contact Andrew White at (508) 616-5550, x227. (AMEX:RGN) (www.

darwin hearings

The conference features scientific updates on prion proteins and strategies
to help industry executives track progress on the development of diagnostic
tests to improve the quality and cost of monitoring TSE infectivity .

Business Editors/Health/Medical Writers
BIOWIRE2K

BETHESDA, Md. in Biochemistry from the American University of Beirut, Beirut,
Lebanon, is fluent in three languages and has been directly involved
in pharmaceutical clinical trials in the U.S. Finkelstein, RegeneRx's president and
CEO . Due to the nature of
clinical trials, product development and the regulatory approval
process , the forward-looking statements contained in this press
release are subject to risks and uncertainties , including those
reflected in the Company's filings with the Securities and Exchange
Commission , particularly its most recent Annual Report on Form 10-KSB.
The Company assumes no obligation to update or revise any
forward-looking statements made herein or any other forward-looking
statements made by the Company.

collaborations biotechnology

IBCLifeSciences. T&F Informa was created through the merger of Informa Group plc and
Taylor & Francis Group plc in May 2004.

biotechnology pharmacogenomics

To download the TSE brochure, visit: http://www .regenerx.D. The company holds over fifty world-wide patents and patent
applications related to dermal , ocular, and internal wounds and tissue
repair, including the treatment and prevention of cardiac and
neurological injuries.

regulatory biotechnology

com/TSEwww., a division of T&F Informa plc (London:
TFI).IBCLifeSciences .

biotechnology hearings

Scientists will gather at the IBC Life Sciences Second Annual Transmissible
Spongiform Encephalopathies (TSE) conference to examine information needed
for the development of risk assessment plans and control procedures.





www.----RegeneRx
Biopharmaceuticals , Inc.

pharmacogenomics collaborations

The two companies are market
leaders in providing specialist information to commercial and academic
markets through conferences and trade events, as well as the publication of
academic , scientific and professional books, journals and newsletters.S.

rumors breakthroughs

These statements concern the
Company 's current expectations regarding future events, including the
regulatory approval process and the ongoing and prospective
development and commercialization of TB4 and possible future benefits
to the Company, its stockholders, and patients.

pharmaceuticals grouped

com) announced that
Nabila Turjman, Ph. and abroad during most
of her regulatory career.

fda vinters

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)